Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2025-08-14 00:00:00 ET · period of report 2025-08-12 · accession 0001724311-25-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-14 | 2025-08-12 | DNLI | Schuth Alexander O. | COFO, Sec | S - Sale | $13.58 | -2,937 | 242.3K | -1% | -$39.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-12 | S | D | 2,937 | $13.58 | 242,346 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.35 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 128,405 Unvested RSUs. (F4) Includes 975 shares acquired under the ESPP Purchase on June 2, 2025. |